Arch Therapeutics Stock Price, News & Analysis (OTCMKTS:ARTH)

$0.77 0.00 (0.00 %)
(As of 12/14/2017 01:04 AM ET)
Previous Close$0.78
Today's Range$0.73 - $0.78
52-Week Range$0.41 - $0.89
Volume134,871 shs
Average Volume389,792 shs
Market Capitalization$116.99 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13

About Arch Therapeutics (OTCMKTS:ARTH)

Arch Therapeutics logoArch Therapeutics, Inc. is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company's technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company's primary product candidates, collectively known as the AC5 Devices (AC5), are designed to achieve hemostasis in surgical procedures. The Company's product candidates rely on its self-assembling peptide technology and are designed to achieve hemostasis in skin wounds, and minimally invasive and open surgical procedures. The Company focuses on developing other product candidates based on its technology platform for use in a range of indications. As of September 30, 2016, the Company had not generated any revenues.

Receive ARTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ARTH
CUSIPN/A
Phone617-431-2313

Debt

Debt-to-Equity RatioN/A
Current Ratio14.12%
Quick Ratio14.12%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book77.00

Profitability

Trailing EPS($0.04)
Net Income$-7,780,000.00
Net MarginsN/A
Return on Equity-246.16%
Return on Assets-130.60%

Miscellaneous

Employees10
Outstanding Shares153,930,000

Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions

What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) issued its earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). View Arch Therapeutics' Earnings History.

Where is Arch Therapeutics' stock going? Where will Arch Therapeutics' stock price be in 2017?

4 brokerages have issued 12-month target prices for Arch Therapeutics' stock. Their forecasts range from $2.50 to $3.00. On average, they anticipate Arch Therapeutics' stock price to reach $2.83 in the next twelve months. View Analyst Ratings for Arch Therapeutics.

Who are some of Arch Therapeutics' key competitors?

Who are Arch Therapeutics' key executives?

Arch Therapeutics' management team includes the folowing people:

  • Avtar S. Dhillon M.D., Chairman of the Board (Age 56)
  • Terrence W. Norchi M.D., President, Chief Executive Officer, Director (Age 49)
  • Richard E. Davis, Chief Financial Officer, Treasurer (Age 55)
  • James R. Sulat, Independent Director (Age 66)

How do I buy Arch Therapeutics stock?

Shares of Arch Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arch Therapeutics' stock price today?

One share of Arch Therapeutics stock can currently be purchased for approximately $0.77.

How big of a company is Arch Therapeutics?

Arch Therapeutics has a market capitalization of $116.99 million. The biotechnology company earns $-7,780,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Arch Therapeutics employs 10 workers across the globe.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]


MarketBeat Community Rating for Arch Therapeutics (ARTH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  126
MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arch Therapeutics (OTCMKTS:ARTH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.83$2.83$2.83$2.83
Price Target Upside: 255.18% upside255.18% upside313.93% upside444.98% upside

Arch Therapeutics (OTCMKTS:ARTH) Consensus Price Target History

Price Target History for Arch Therapeutics (OTCMKTS:ARTH)

Arch Therapeutics (OTCMKTS:ARTH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
9/18/2017HC WainwrightReiterated RatingBuy$3.00View Rating Details
7/25/2017Ifs SecuritiesReiterated RatingOutperformView Rating Details
5/25/2017Roth CapitalSet Price TargetBuy$3.00View Rating Details
2/13/2017Rodman & RenshawInitiated CoverageBuy$2.50View Rating Details
(Data available from 12/14/2015 forward)

Earnings

Arch Therapeutics (OTCMKTS:ARTH) Earnings History and Estimates Chart

Earnings by Quarter for Arch Therapeutics (OTCMKTS:ARTH)

Arch Therapeutics (OTCMKTS ARTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q2 2017($0.01)($0.01)ViewN/AView Earnings Details
2/1/2017Q1 2017($0.01)ViewN/AView Earnings Details
12/5/2016Q4 2016($0.01)($0.01)ViewN/AView Earnings Details
2/12/2016Q1($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Arch Therapeutics (OTCMKTS:ARTH) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.05 EPS
Next Year EPS Consensus Estimate: $-0.03 EPS

Dividends

Dividend History for Arch Therapeutics (OTCMKTS:ARTH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Arch Therapeutics (OTCMKTS ARTH)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Arch Therapeutics (OTCMKTS ARTH) News Headlines

Source:
DateHeadline
Contrasting Integer (ITGR) and Arch Therapeutics (ARTH)Contrasting Integer (ITGR) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - December 11 at 7:42 PM
Critical Contrast: Arch Therapeutics (ARTH) versus AxoGen (AXGN)Critical Contrast: Arch Therapeutics (ARTH) versus AxoGen (AXGN)
www.americanbankingnews.com - December 8 at 5:14 PM
Reviewing Arch Therapeutics (ARTH) & AxoGen (AXGN)Reviewing Arch Therapeutics (ARTH) & AxoGen (AXGN)
www.americanbankingnews.com - December 8 at 8:40 AM
AxoGen (AXGN) vs. Arch Therapeutics (ARTH) Head to Head ContrastAxoGen (AXGN) vs. Arch Therapeutics (ARTH) Head to Head Contrast
www.americanbankingnews.com - December 7 at 5:30 PM
Arch Therapeutics (ARTH) Lifted to "Buy" at Zacks Investment ResearchArch Therapeutics (ARTH) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - December 1 at 8:42 PM
Contrasting Arch Therapeutics (ARTH) & AxoGen (AXGN)Contrasting Arch Therapeutics (ARTH) & AxoGen (AXGN)
www.americanbankingnews.com - November 30 at 5:28 PM
Arch Therapeutics, Inc. (ARTH) Given Consensus Rating of "Buy" by BrokeragesArch Therapeutics, Inc. (ARTH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 30 at 7:50 AM
Reviewing Integer (ITGR) and Arch Therapeutics (ARTH)Reviewing Integer (ITGR) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - November 29 at 7:26 PM
Analyzing AxoGen (AXGN) and Arch Therapeutics (ARTH)Analyzing AxoGen (AXGN) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - November 28 at 7:10 PM
Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7 ... - GlobeNewswire (press release)Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7 ... - GlobeNewswire (press release)
globenewswire.com - November 28 at 6:13 PM
Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017
finance.yahoo.com - November 28 at 9:25 AM
Contrasting AxoGen (AXGN) & Arch Therapeutics (ARTH)Contrasting AxoGen (AXGN) & Arch Therapeutics (ARTH)
www.americanbankingnews.com - November 28 at 1:08 AM
Arch Therapeutics (ARTH) vs. Integer (ITGR) Head to Head SurveyArch Therapeutics (ARTH) vs. Integer (ITGR) Head to Head Survey
www.americanbankingnews.com - November 28 at 1:08 AM
Arch Therapeutics (ARTH) and Medtronic (MDT) Head to Head ReviewArch Therapeutics (ARTH) and Medtronic (MDT) Head to Head Review
www.americanbankingnews.com - November 27 at 10:10 AM
AxoGen (AXGN) and Arch Therapeutics (ARTH) Head to Head ComparisonAxoGen (AXGN) and Arch Therapeutics (ARTH) Head to Head Comparison
www.americanbankingnews.com - November 25 at 1:16 PM
Financial Review: AxoGen (AXGN) and Arch Therapeutics (ARTH)Financial Review: AxoGen (AXGN) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - November 25 at 3:26 AM
Comparing Arch Therapeutics (ARTH) & Medtronic PLC (MDT)Comparing Arch Therapeutics (ARTH) & Medtronic PLC (MDT)
www.americanbankingnews.com - November 21 at 11:49 AM
Contrasting AxoGen (AXGN) and Arch Therapeutics (ARTH)Contrasting AxoGen (AXGN) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - November 20 at 9:36 PM
Financial Survey: Medtronic PLC (MDT) & Arch Therapeutics (ARTH)Financial Survey: Medtronic PLC (MDT) & Arch Therapeutics (ARTH)
www.americanbankingnews.com - November 19 at 7:14 AM
Arch Therapeutics (ARTH) vs. Integer Holdings Corporation (ITGR) Critical AnalysisArch Therapeutics (ARTH) vs. Integer Holdings Corporation (ITGR) Critical Analysis
www.americanbankingnews.com - November 18 at 5:12 AM
ValuEngine Lowers Arch Therapeutics, Inc. (ARTH) to SellValuEngine Lowers Arch Therapeutics, Inc. (ARTH) to Sell
www.americanbankingnews.com - November 18 at 12:46 AM
Comparing Integer Holdings Corporation (ITGR) and Arch Therapeutics (ARTH)Comparing Integer Holdings Corporation (ITGR) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - November 16 at 1:08 PM

SEC Filings

Arch Therapeutics (OTCMKTS:ARTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Arch Therapeutics (OTCMKTS ARTH) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.